

SPEAKER: The lower the LDL cholesterol, the lower the rate of heart attack, the lower the rate of stroke, and the lower the rate of cardiovascular death. There is no real cut off in the studies that are done that happens at 70 milligrams per deciliter. I think that is a good starting point.

But if the patient is at sufficiently high risk, I tell the patient that I think we should collaboratively shoot to lower the LDL cholesterol level even further. With respect to the cost effectiveness of lowering, with the marked reduction in the price of the PCSK9 inhibitors, I think this will be a new ballgame as we enter the new year, and that this will really increase the availability, the accessibility of the PCSK9 inhibitors. And in addition, I expect over time, just as has happened with Entresto, the need for doing a prior authorization form and the need for additional paperwork will be markedly reduced.